New sheep placenta therapy used to banish wrinkles
A Harley Street doctor has developed an unusual new cosmetic surgery treatment which is being branded as an ‘alternative facelift’.
Rather than utilising a cream or Botox injections, sheep placenta is the main ingredient in the new Actistem treatment, which apparently acts as a cure for wrinkles.
It is thought that sheep placenta contains a protein which, when it comes into contact with skin, can help to stimulate collagen production.
READ MORE FROM THE WDM CONTENT NETWORK:
To read the latest edition of Healthcare Global, click here
- New rules may allow abortion clinics to advertise on TV
- New pill has ALL five-a-day fruit and vegetable needs
- Danish drug banned in US executions
According to Dr Roberto Veil, the brains behind the treatment, the placenta is full of stem cells which replenishes the skin and encourages the production of collagen and elastin, resulting in a skin firming effect.
Patients who undergo the Actistem procedure have an anaesthetic cream applied to their face, which is followed by a dermaroller treatment to stimulate the blood flow in the skin.
This is followed by the application of the sheep placenta, a clear, thick, liquid, which is massaged into the face.
Dr Weil repeats the process three times as part of one treatment and after three days patients will notice an improvement in skin texture.
After two weeks the elastin and collagen count in the skin increases and it will be lifted and tightened, reducing the appearance of wrinkles.
The sheep placenta is imported to Dr Veil’s London Centre for Aesthetic Surgery from Australia and the Actistem treatments take 30 mintues, cost £600 and results can last up to five months.
Skin Analytics wins NHSX award for AI skin cancer tool
An artificial intelligence-driven tool that identifies skin cancers has received an award from NHSX, the NHS England and Department of Health and Social Care's initiative to bring technology into the UK's national health system.
NHSX has granted the Artificial Intelligence in Health and Care Award to DERM, an AI solution that can identify 11 types of skin lesion.
Developed by Skin Analytics, DERM analyses images of skin lesions using algorithms. Within primary care, Skin Analytics will be used as an additional tool to help doctors with their decision making.
In secondary care, it enables AI telehealth hubs to support dermatologists with triage, directing patients to the right next step. This will help speed up diagnosis, and patients with benign skin lesions can be identified earlier, redirecting them away from dermatology departments that are at full capacity due to the COVID-19 backlog.
Cancer Research has called the impact of the pandemic on cancer services "devastating", with a 42% drop in the number of people starting cancer treatment after screening.
DERM is already in use at University Hospitals Birmingham and Mid and South Essex Health & Care Partnership, where it has led to a significant reduction in unnecessary referrals to hospital.
Now NHSX have granted it the Phase 4 AI in Health and Care Award, making DERM available to clinicians across the country. Overall this award makes £140 million available over four years to accelerate the use of artificial intelligence technologies which meet the aims of the NHS Long Term Plan.
Dr Lucy Thomas, Consultant Dermatologist at Chelsea & Westminster Hospital, said: “Skin Analytics’ receipt of this award is great news for the NHS and dermatology departments. It will allow us to gather real-world data to demonstrate the benefits of AI on patient pathways and workforce challenges.
"Like many services, dermatology has severe backlogs due to the COVID-19 pandemic. This award couldn't have come at a better time to aid recovery and give us more time with the patients most in need of our help.”